Patents Represented by Attorney Laura Butterfield Arciniegas
  • Patent number: 8044051
    Abstract: Methods are provided for preparation of compositions having an enhanced level of soluble alloxazine, as compared to compositions prepared using conventional techniques. Compositions and a riboflavin form having higher solubility in solution is also provided.
    Type: Grant
    Filed: January 24, 2007
    Date of Patent: October 25, 2011
    Assignee: CaridianBCT Biotechnologies, LLC
    Inventors: Eric T. Hansen, Raymond P. Goodrich
  • Patent number: 8017110
    Abstract: A process for damaging and maintaining damage to the nucleic acids of pathogens such as white blood cells, bacteria and viruses which may be contained in blood or blood components. This process comprises adding to the blood or blood component containing pathogens an effective amount of riboflavin, and exposing the fluid to light of an appropriate wavelength to damage the nucleic acid of the pathogen and to substantially maintain the damage to the pathogenic nucleic acids to allow for subsequent transfusion into a recipient.
    Type: Grant
    Filed: June 8, 2011
    Date of Patent: September 13, 2011
    Assignee: CaridianBCT Biotechnologies, LLC
    Inventors: Raymond P. Goodrich, Shawn D. Keil, Robert Owen Lockerbie, Vijay Kumar
  • Patent number: 7985588
    Abstract: A process for damaging and maintaining damage to the nucleic acids of pathogens such as white blood cells, bacteria and viruses which may be contained in blood or blood components. This process comprises adding to the blood or blood component containing pathogens an effective amount of riboflavin, and exposing the fluid to light of an appropriate wavelength to damage the nucleic acid of the pathogen and to substantially maintain the damage to the pathogenic nucleic acids to allow for subsequent transfusion into a recipient.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: July 26, 2011
    Assignee: CaridianBCT Biotechnologies, LLC
    Inventors: Raymond P. Goodrich, Shawn D. Keil
  • Patent number: 7498156
    Abstract: This invention is directed towards a method of using visible light at wavelengths of at least 500 nm and above in combination with a sensitizer having a flavin moiety to reduce any pathogens that may be contained in blood and blood components. By exposing the blood and blood components to light of 500 nm and higher, only the sensitizer that is bound to nucleic acids of the pathogens will be activated, thus destroying the sensitizer-pathogenic nucleic acid complex. Because unbound sensitizer is not activated at this wavelength, damage to blood and blood components caused by photolysis of unbound sensitizer may be avoided.
    Type: Grant
    Filed: June 15, 2005
    Date of Patent: March 3, 2009
    Assignees: CaridianBCT Biotechnologies, LLC, Ohio State University Research Foundation
    Inventors: Raymond P. Goodrich, Matthew S. Platz, Christopher B. Martin
  • Patent number: 7052606
    Abstract: A method and apparatus for red blood collection and filtration is provided wherein a red blood cell collection assembly provides for leukoreduction filtration concurrent with or soon after the red blood cell separation and collection procedure. Such procedures involve filtering the separated red blood cells in a diluted state after and/or prior to flushing the filter with storage solution. Storage solution may thus be passed through the leukoreduction filter before, with and/or after the RBCs have been filtered therethrough. The red blood cell collection, filtration and storage assembly is preferably preconnected to a blood component separation disposable assembly, including, for example, a centrifuge vessel and a blood removal/return assembly for removing blood from a donor, passing the blood to the centrifuge vessel for separation of the blood into components for collection and providing for filtration of the separated red blood cell component.
    Type: Grant
    Filed: December 10, 2002
    Date of Patent: May 30, 2006
    Assignee: Gambro, Inc.
    Inventors: Bruce M. Gibbs, Jon D. Herskovits